Patenting mutations

Published: Wednesday 15 April 1998

Myriad Genetics, a noted biotechnology company based in Washington, USA, recently announced that it had been awarded a patent on 47 different mutations in the BRCA1 gene, abnormalities in which substantially heighten risk of such diseases as breast and ovarian cancer. According to Peter Meldrum, Myriad's president and chief executive officer, the award "establishes a broad and substantial proprietary foundation for the company's products."

Subscribe to Daily Newsletter :

Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.